&w=3840&q=100)
Obesity injections may have less weight loss effect in reality: Study
Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found.
Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar.
The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting.
"Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said.
"According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomised clinical trial settings," Dr Gasoyan said.
The researchers examined 7,881 adult patients with an average body mass index (BMI) of over 39 -- classified as 'severe obesity'. Of these, 1,320 had pre-diabetes at the start of the study, which meant they were at a higher risk of developing type 2 diabetes.
The participants were started on obesity treatments between 2021 and 2023 with semaglutide or tirzepatide injectables.
Following up on the participants a year after starting with the treatment, the average weight loss among those who discontinued injections within three months was 3.6 per cent, compared to 6.8 per cent in those who discontinued within 3-12 months.
"Mean percentage weight reduction at one year was 8.7 per cent, and it was 3.6 per cent with early discontinuation (three months), 6.8 per cent with late discontinuation (3-12 months) and 11.9 per cent with no discontinuation," the authors wrote.
Furthermore, those on a high-maintenance dosage -- the amount required to sustain the effects of the medication -- lost 13.7 per cent of their body weight with semaglutide and 18 per cent with tirzepatide, the researchers said.
Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment.
"The average weight reduction in this cohort was lower than that observed in the main phase 3 (clinical) trials, likely because of higher rates of discontinuation and lower maintenance dosages," the team wrote.
They identified that those not discontinuing medications or taking a high-maintenance dose were among the factors related to more chances of losing at least 10 per cent of one's body weight in a year.
Overall, over a fifth of the study group was found to have discontinued their medications within three months of the study's start, while 32 per cent discontinued within 3-12 months.
Reasons for discontinuing treatment included costs and insurance-related issues, side effects and medication shortages, the researchers said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
an hour ago
- Hindustan Times
Cardiac surgeon reveals why silent heart attacks are a risk for even young and fit Indians: Causes to prevention tips
Can you have a heart attack and not know it? Silent heart attacks can be particularly dangerous because they often go unnoticed, and the damage may only be discovered later. In an interview with HT Lifestyle, Dr Niranjan Hiremath, senior consultant and cardiovascular and aortic surgeon at Apollo Indraprastha, New Delhi, said that silent heart attacks are a growing concern among young Indians. Also read | Cardiologist warns of alarming rise in heart attacks among young smokers under 40: Know symptoms, causes and prevention Dr Hiremath said, 'It's an alarming thought — someone in their 30s or 40s, apparently healthy and active, suddenly collapses or ends up in an emergency room, diagnosed with a heart attack, which they never saw coming. These are not just rare exceptions anymore. In this digital era, increasingly, cases of 'silent heart attacks' are being reported among youngsters, who show no obvious signs of heart trouble.' Estimates suggest that 22 percent to 60 percent of all heart attacks are silent, and that such attacks may be more common in women or people with diabetes, according to the Cleveland Clinic. But what exactly is a silent heart attack, and why is it affecting people who appear to be in the prime of their health? Dr Hiremath said: 'Unlike the dramatic chest-clutching scenes we generally associate with heart attacks, a silent heart attack can occur with little or no noticeable indications. Medically known as a 'silent myocardial infarction' — it damages the heart muscle just like a regular heart attack, but goes overlooked, often until much later.' He added that sometimes, symptoms are so mild or unusual that they are brushed off as fatigue, acidity, gas-related problems or muscle pain. According to Dr Hiremath, the stereotype of a heart patient being overweight, sedentary, or elderly no longer stands. He said that 'many teens with healthy-looking bodies and active lifestyles are now part of heart disease statistics. 'Stressful work environments, irregular sleep cycles, processed foods, smoking, drinking, and excessive gym routines without proper heart checks are all part of the problem,' Dr Hiremath said. He added, 'Another major risk factor is genetics. In general, Indians are genetically more prone to heart disease at an earlier age due to smaller coronary arteries and a higher prevalence of diabetes and cholesterol issues. So even if someone looks fit from the outside due to their physique, they may be carrying silent risk factors inside.' The tricky part about silent heart attacks is the lack of typical symptoms. 'But some subtle signs can still be there — mild chest discomfort, breathlessness during exercise, unexplained fatigue, pain in the jaw, neck or arms, dizziness, or indigestion-like discomfort – which are often ignored or misread as something harmless, especially by the youth,' Dr Hiremath said. He added, 'It's also common for people to assume that being slim or going to the gym daily automatically protects them from heart related issues. But physical appearance or physique doesn't always reflect what's going on inside the arteries.' Even if you're a teen and have no symptoms, according to Dr Hiremath, getting an annual health check-up — including ECG (electrocardiogram), cholesterol tests, blood pressure, and if necessary, a stress test — can help detect early warning signs. He said, 'Individual with family history of heart disease, diabetes, or high blood pressure should be extra cautious. Also, fitness should be holistic — combining regular exercise and gym, a balanced diet, adequate sleep, and stress management. Over-exercising without medical clearance or extreme dieting can do more harm than good.' Dr Hiremath also spoke about how by being aware of the risks and taking proactive steps, people can reduce their likelihood of experiencing a silent heart attack and improve their overall cardiovascular health. He suggested you start with small, sustainable lifestyle changes: 'Quit smoking, cut down on processed food and sugar and manage your weight. Also, practice yoga, meditation or deep breathing to control stress. Sleep at least 7–8 hours daily. And most importantly, don't ignore what your body is trying to tell you. If something feels off/bad, get it checked.' 'The face of heart disease in India is changing. It's no longer about age — it's about awareness. A silent heart attack doesn't announce its arrival, but the damage it causes can be lifelong or, worse, fatal. Whether you're a busy professional, a gym enthusiast, or just someone who feels fine, your heart deserves attention. Don't wait for a warning or signs — stay ahead of it,' Dr Hiremath concluded. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Time of India
18 hours ago
- Time of India
JD Vance's wild take on weight loss drug Ozempic sparks criticism
Politicians usually avoid cracking jokes about eating habits—especially when it comes to weight loss drugs. But not JD Vance. The Vice President of the United States stunned listeners with a strange and awkward take on the popular diabetes and weight loss drug Ozempic, casually tossing in a cannibalism reference that many are calling "gross" and "tone-deaf. Tired of too many ads? go ad free now " On a recent appearance on comedian Theo Von's podcast, Vance launched into an unscripted riff about a medical commercial he'd seen. 'I only saw it briefly,' he said, 'but I could have sworn that two of the medications in this med pack were—Ivermectin and Ozempic. And I'm like thinking to myself, what is the situation where you need emergency Ozempic?' Then came the part that really raised eyebrows. With a laugh, Vance added, 'I thought like, you know, if you have a Donner Party situation... and it's like alright, we gotta suppress our appetites.' Wait—what? What was the Donner Party? Credit: X/@pitsenberger To decode Vance's joke, you'd have to go back to 1846, when a group of American pioneers known as the Donner Party became stranded in the Sierra Nevada mountains while traveling to California. With winter closing in and food supplies exhausted, some members of the group reportedly resorted to cannibalism to survive. It's a dark, tragic chapter in American history—and probably not the best setup for a punchline about a modern weight-loss drug. Social media reactions Social media lit up in the hours after the podcast aired, with critics slamming Vance for making light of both the desperation of the Donner Party and the medical struggles of people using Ozempic. Many pointed out that the drug is not just used by people who want to lose weight, but is also used by diabetes patients. One user commented, 'Ozempic was designed for patients with diabetes, and people with the disease also use it, J Dunce. Diabetes can be caused by other conditions, like pancreatitis and pregnancy. ' Another commented, 'What kinda of #weirdo uses "Donner Party" as the metric to evaluate bulimic therapy???' A third said, 'Why is he talking like he is expert on something he doesn't know about? Ozempic is a diabetic drug. Tired of too many ads? go ad free now It helps to regulate sugar in diabetics.' What is Ozempic? Ozempic is a prescription medication primarily used to help manage type 2 diabetes. It works by mimicking a natural hormone that regulates blood sugar levels and slows digestion, which can help people feel fuller for longer. While not originally developed as a weight loss drug, one of its side effects is appetite suppression—leading to noticeable weight loss in many patients. In recent years, Ozempic has entered the public conversation beyond diabetes care, with growing demand among people seeking medical help for obesity.
Time of India
19 hours ago
- Time of India
McDonald's downgraded amid Ozempic craze - investors worry fast food losing charm, stock under pressure
McDonald's stock was downgraded by analysts following concerns that weight-loss drugs like Ozempic could curb fast-food demand. Analysts suggested that these drugs, which reduce appetite, might lead to a significant drop in customer visits, potentially costing the company millions in revenue. Tired of too many ads? Remove Ads Equity Firm Downgrades McDonald's Stock How GLP-1 Medications Could Disrupt Fast Food Demand McDonald's Potential Revenue Losses and Customer Visit Declines Tired of too many ads? Remove Ads Inflation Adds Fuel to McDonald's Challenges Not Many Americans Are Using These Drugs Yet FAQs McDonald's faced a rough day on Wall Street Tuesday as shares dipped 1.7%, shaken by growing concerns that popular weight-loss drugs like Ozempic could seriously cut into the fast food giant's business, as per a analysis firm Redburn Atlantic lowered its rating on McDonald's stock by two notches from 'buy' to 'sell,' warning that the widespread use of GLP-1 drugs, which curb appetite and help regulate blood sugar, may change how Americans eat, potentially leading to a drop in millions of visits to McDonald's every year, as per CBS Redburn analysis described GLP-1 drugs like Ozempic and Wegovy as "demand disruptors" for restaurants like McDonald's , as they reduce consumers' appetites and limit the number of calories they consume each day, reported CBS News. Analysts wrote that, "These features of the drugs could have serious implications for the restaurant industry," according to the READ: YouTube loosens content rules, says freedom of expression can outweigh harm—controversial videos may return Analysts Chris Luyckx and Edward Lewis estimated that McDonald's could lose up to 28 million customer visits annually, resulting in nearly $482 million in lost revenue, roughly 0.9% of the company's sales, according to the concern is that GLP-1 drugs may shift eating habits, especially among lower-income consumers, who are the fast food chain's target market and who might cut back on dining out and keep those new habits long-term, as per CBS analysts pointed out that the "Behaviour changes extend beyond the individual user — reshaping group dining, influencing household routines and softening habitual demand. A 1% drag today could easily build to 10% or more over time, particularly for brands skewed toward lower income consumers or group occasions," quoted CBS to the pressure, rising prices and inflation might make it even harder for McDonald's to maintain its appeal to its customers, as per the report. The analysts highlighted that, "Consumers are showing clear signs of pricing fatigue after years of aggressive menu inflation," adding, "Although the gap between eating out and at home has narrowed, it remains historically wide, reinforcing value concerns," quoted CBS the adoption of the GLP-1 drugs has yet to reach a wider audience, as only 12% of Americans have tried the drugs, and currently just 6% of the adult population uses them, as per the the managing director and restaurant and food distributors analyst at BTIG global financial services, Peter Saleh said, "I don't think there would be a meaningful GLP-1 impact on McDonald's right now, but that's not to say that in three or four years that won't be the case," adding, "I just don't think we are there yet," quoted CBS medications that help regulate blood sugar and suppress appetite, often used for weight loss, as per to $482 million a year, according to some analysts.
